Literature DB >> 31977241

Assessment of robustness against setup uncertainties using probabilistic scenarios in lung cancer: a comparison of proton with photon therapy.

Suliana Teoh1,2, Ben George1,2, Francesca Fiorini1,3, Katherine A Vallis1,2, Frank Van den Heuvel1,2.   

Abstract

OBJECTIVE: We compared the sensitivity of intensity modulated proton therapy (IMPT) and photon volumetric modulated arc therapy (VMAT) plans to setup uncertainties in locally advanced non-small cell lung cancer (NSCLC) using probabilistic scenarios.
METHODS: Minimax robust (MM) and planning target volume (PTV) optimised IMPT and VMAT nominal plans were created with physical dose of 70 Gy in 35 fractions in 10 representative patients. Using population data of setup errors, a fractionated treatment course was simulated, summed (Dsum) and compared to the nominal plan. Three treatment-course simulations were done for each plan. Target robustness criteria were: dose deviation of ≤5% to clinical target volume (CTV) D98% and CTV V95% ≥ 99.9%. Voxelwise simulation repeatability was analysed using Bland-Altman plots. Acceptable limits of agreement were 2% of the prescription dose.
RESULTS: All Dsum met target robustness criteria. While fraction VMAT and MM-IMPT doses were excellent, simulated fraction doses in PTV-IMPT were suboptimal. Almost all (>99%) of VMAT and MM-IMPT fraction doses met both target robustness criteria. For PTV-IMPT, only 96.9 and 80.3% of fractions met CTVD98% and V95% criteria respectively. Simulation repeatability was excellent (limits of agreement range: 0.41-1.1 Gy) with strong positive correlations.
CONCLUSION: When considering the whole treatment course, setup errors do not influence robustness irrespective of planning techniques used. However, on a fraction level, VMAT and MM-IMPT plans are superior compared to PTV-IMPT plans. ADVANCES IN KNOWLEDGE: Probabilistic analysis provides a fast and practical method for evaluating VMAT and IMPT plan sensitivity against setup uncertainty. VMAT and robust-optimised IMPT plans have comparable sensitivity to setup uncertainties in conventionally fractionated treatment for NSCLC.

Entities:  

Mesh:

Year:  2020        PMID: 31977241      PMCID: PMC7066956          DOI: 10.1259/bjr.20190584

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.629


  23 in total

1.  Robust optimization of intensity modulated proton therapy.

Authors:  Wei Liu; Xiaodong Zhang; Yupeng Li; Radhe Mohan
Journal:  Med Phys       Date:  2012-02       Impact factor: 4.071

2.  An application of Bayesian statistical methods to adaptive radiotherapy.

Authors:  Kwok L Lam; Randall K Ten Haken; Dale Litzenberg; James M Balter; Stephen M Pollock
Journal:  Phys Med Biol       Date:  2005-08-02       Impact factor: 3.609

3.  Worst case optimization: a method to account for uncertainties in the optimization of intensity modulated proton therapy.

Authors:  D Pflugfelder; J J Wilkens; U Oelfke
Journal:  Phys Med Biol       Date:  2008-02-29       Impact factor: 3.609

4.  Minimax optimization for handling range and setup uncertainties in proton therapy.

Authors:  Albin Fredriksson; Anders Forsgren; Björn Hårdemark
Journal:  Med Phys       Date:  2011-03       Impact factor: 4.071

5.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

6.  Robustness Recipes for Minimax Robust Optimization in Intensity Modulated Proton Therapy for Oropharyngeal Cancer Patients.

Authors:  Sebastian van der Voort; Steven van de Water; Zoltán Perkó; Ben Heijmen; Danny Lathouwers; Mischa Hoogeman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-02-16       Impact factor: 7.038

Review 7.  Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee.

Authors:  Joe Y Chang; Xiaodong Zhang; Antje Knopf; Heng Li; Shinichiro Mori; Lei Dong; Hsiao-Ming Lu; Wei Liu; Shahed N Badiyan; Stephen Both; Arturs Meijers; Liyong Lin; Stella Flampouri; Zuofeng Li; Kikuo Umegaki; Charles B Simone; Xiaorong R Zhu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-05-19       Impact factor: 7.038

8.  Impact of fractionation and number of fields on dose homogeneity for intra-fractionally moving lung tumors using scanned carbon ion treatment.

Authors:  Jens Wölfelschneider; Thomas Friedrich; Robert Lüchtenborg; Klemens Zink; Michael Scholz; Lei Dong; Marco Durante; Christoph Bert
Journal:  Radiother Oncol       Date:  2015-12-29       Impact factor: 6.280

9.  Incorporating the effect of fractionation in the evaluation of proton plan robustness to setup errors.

Authors:  Matthew Lowe; Francesca Albertini; Adam Aitkenhead; Antony J Lomax; Ranald I MacKay
Journal:  Phys Med Biol       Date:  2015-12-16       Impact factor: 3.609

10.  Technical Note: Defining cyclotron-based clinical scanning proton machines in a FLUKA Monte Carlo system.

Authors:  Francesca Fiorini; Niek Schreuder; Frank Van den Heuvel
Journal:  Med Phys       Date:  2017-12-22       Impact factor: 4.071

View more
  3 in total

1.  Proton therapy special feature: introductory editorial.

Authors:  Kathryn D Held; Antony J Lomax; Esther G C Troost
Journal:  Br J Radiol       Date:  2020-03       Impact factor: 3.039

2.  Evaluation of Plan Robustness Using Hybrid Intensity-Modulated Radiotherapy (IMRT) and Volumetric Arc Modulation Radiotherapy (VMAT) for Left-Sided Breast Cancer.

Authors:  Zhen Ding; Qi Zeng; Kailian Kang; Meiling Xu; Xiaoyong Xiang; Chenbin Liu
Journal:  Bioengineering (Basel)       Date:  2022-03-24

3.  Assessment of a diaphragm override strategy for robustly optimized proton therapy planning for esophageal cancer patients.

Authors:  Sabine Visser; Hendrike Neh; Cássia Oraboni Ribeiro; Erik W Korevaar; Arturs Meijers; Björn Poppe; Nanna M Sijtsema; Stefan Both; Johannes A Langendijk; Christina T Muijs; Antje C Knopf
Journal:  Med Phys       Date:  2021-08-05       Impact factor: 4.506

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.